SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 6904
  • 2
    Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes Control 1999; 10: 24551
  • 3
    Philip J, Rogers B, Parr NJ. Effect of very low fat diet on progressive prostate cancer: experience from a dedicated clinic. Prost Cancer Prost Dis 2006; 9: 326
  • 4
    Wadwha V, Weston R, Parr NJ. Comparison of longitudinal changes in bone mineral density in advanced prostate cancer patients treated with androgen ablation or anti-androgen hormonal therapy. J Urol 2005; 173 (Suppl 4): 221
  • 5
    Sieber P, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localised or locally advanced prostate cancer. J Urol 2004; 171: 22726
  • 6
    Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostate cancer treated with orchidectomy and with oestrogens. Calcif Tissue Int 1995; 57: 979
  • 7
    Wadwha V, Weston R, Parr NJ. Zoledronic acid to prevent further bone loss in osteoporotic patients requiring androgen-deprivation therapy for prostate cancer. BJU Int 2006; 97 (Suppl 3): 101, Abstract
  • 8
    Hoer A, Göl D, Gothe H, Schiffhorst G, Brandman J, Häussler B. Rates and determinants of patient persistency with oral bisphosphonates in cancer patients. 17th MASCC International Symposium June 2005: Geneva, Switzerland, 428, Abstract 07–057. Available at: http://www.mascc.org/media/Symposium/Springer_MASCC_abstracts05.pdf. Accessed November 2006